生物制药是近年来医药行业中增长最迅速的行业之一，治疗性抗体作为生物药物中最耀眼的明珠已成为生物制药的最大产品类别，约占生物制药的35%。抗体药物在治疗以肿瘤为主的人类多种疾病方面起着重要作用。2011年，全球抗体药物的销售额达到480亿美元。我国当前正处在抗体药物快速发展阶段，目前SFDA共批准了17种单抗。预计到2015年，我国抗体销售额将达到325～650亿元。从产品来看，虽然我国已经有所突破，但数量和类型上，与国外的抗体药物还有很大差距。随着生物技术的不断发展，抗体药物的市场前景将会越来越广泛。

In recent years, biopharmaceuticals has become one of the fastest growing businesses in medicinal industry. Therapeutic antibody, accounting for about 35% of the biopharmaceuticals, has become the largest biopharmaceutical product category. Antibody drugs play an important effect in the treatment of a number of human diseases, especially in antitumor. In 2011, the global sales of antibody drugs have reached 48 billion dollar. Currently, China is in the initial stage of the rapid development of antibody drugs. At present, 17 kinds of monoclonal antibodies were approved by SFDA. In 2015, it is estimated that the sales of antibody drugs of China will be 32.5—65.0 billion Yuan. Although we had a breakthrough in antibody products, we still have a big gap compared with the developed countries in amounts and types. With the continuous development of biotechnology, the market prospects of antibody drugs will become more and more extensive.